Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study

Acta Ophthalmologica

Volumn 89, Issue 3, 2011, Pages 208-217

  Tano, Yasuo ^a   Ohji, Masahito ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

age related macular degeneration; best corrected visual acuity score; efficacy; individualized flexible interval regimen; Japanese patients; PRN; ranibizumab; safety; subfoveal choroidal neovascularization

Indexed keywords

RANIBIZUMAB;

ABSCESS; ABSCESS NECK; AGED; ALLERGIC CONJUNCTIVITIS; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; ASTHENOPIA; BLOOD PRESSURE; BRAIN INFARCTION; CATARACT; COLON CANCER; COLON POLYP; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DEMENTIA; DENTAL CARIES; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EMPHYSEMA; ENTEROCELE; EYE DISEASE; EYE INFLAMMATION; EYE PAIN; FALLING; FEMALE; GASTROENTERITIS; GLAUCOMATOCYCLITIC CRISIS; HEMATURIA; HUMAN; HYPERTENSION; HYPOPYON; INJECTION SITE DISCOMFORT; INJURY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRITIS; JAPANESE; LONGITUDINAL STUDY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYODESOPSIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCTATE KERATITIS; RETINA DETACHMENT; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA MACULOPATHY; RETINA TEAR; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL CORD DISEASE; STOMACH CANCER; STOMACH POLYP; SUBRETINAL NEOVASCULARIZATION; UVEITIS; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION; VITREOUS HEMORRHAGE; VITRITIS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79955043800     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.02065.x     Document Type: Article

References (13)

1. Bressler NM, (2004): Age-related macular degeneration is the leading cause of blindness. JAMA 291: 1900-1901. (Pubitemid 38509505)
2. Brown DM, Kaiser PK, Michels M, et al., (2006): Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444. (Pubitemid 44511558)
3. Brown DM, Michels M, Kaiser PK, et al., (2009): Ranibizumab versus Verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
4. Ferrara N, Damico L, Shams N, et al., (2006): Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859-870. (Pubitemid 44547437)
5. Ferrara N, Mass RD, Campa C, &, Kim R, (2007): Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58: 491-504. (Pubitemid 46706529)
6. Holz FG, Korobelnik JF, Lanzetta P, et al., (2010): The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 511: 405-412.
7. Kawasaki R, Wang JJ, Ji GJ, et al., (2008): Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 115: 1376-1381.
8. Mitchell P, Korobelnik JF, Lanzetta P, et al., (2010): Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94: 2-13.
9. Oshima Y, Ishibashi T, Murata T, et al., (2001): Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol 85: 1153-1157. (Pubitemid 32929535)
10. Regillo CD, Brown DM, Abraham P, et al., (2008): Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239-248.
11. Rosenfeld PJ, Brown DM, Heier JS, et al., (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431. (Pubitemid 44511557)
12. Tano Y, &, Ohji M, (2010): EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 88: 309-316.
13. Waisbourd M, Loewenstein A, Goldstein M, &, Leibovitch I, (2007): Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 24: 643-662.